Luminex Co. (LMNX) Shares Sold by Zebra Capital Management LLC

Share on StockTwits

Zebra Capital Management LLC lessened its position in shares of Luminex Co. (NASDAQ:LMNX) by 38.3% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 26,880 shares of the medical instruments supplier’s stock after selling 16,681 shares during the period. Zebra Capital Management LLC’s holdings in Luminex were worth $794,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Principal Financial Group Inc. lifted its holdings in shares of Luminex by 2.8% in the 1st quarter. Principal Financial Group Inc. now owns 329,799 shares of the medical instruments supplier’s stock worth $6,949,000 after purchasing an additional 9,050 shares during the last quarter. Los Angeles Capital Management & Equity Research Inc. bought a new stake in shares of Luminex in the 2nd quarter worth approximately $1,187,000. KBC Group NV lifted its holdings in shares of Luminex by 46.7% in the 1st quarter. KBC Group NV now owns 31,797 shares of the medical instruments supplier’s stock worth $670,000 after purchasing an additional 10,122 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of Luminex by 25.6% in the 1st quarter. JPMorgan Chase & Co. now owns 152,092 shares of the medical instruments supplier’s stock worth $3,205,000 after purchasing an additional 30,969 shares during the last quarter. Finally, Candriam Luxembourg S.C.A. bought a new stake in shares of Luminex in the 1st quarter worth approximately $801,000. 82.23% of the stock is currently owned by institutional investors and hedge funds.

Shares of Luminex stock opened at $29.78 on Friday. The firm has a market cap of $1.31 billion, a price-to-earnings ratio of 32.73, a price-to-earnings-growth ratio of 3.39 and a beta of 0.24. Luminex Co. has a 1-year low of $18.62 and a 1-year high of $35.37.

Luminex (NASDAQ:LMNX) last announced its earnings results on Monday, August 6th. The medical instruments supplier reported $0.15 earnings per share for the quarter, missing the consensus estimate of $0.19 by ($0.04). The business had revenue of $79.60 million for the quarter, compared to the consensus estimate of $79.66 million. Luminex had a net margin of 10.57% and a return on equity of 7.44%. The firm’s revenue was up 4.1% on a year-over-year basis. During the same period in the previous year, the firm earned $0.26 EPS. equities research analysts expect that Luminex Co. will post 0.58 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 12th. Shareholders of record on Friday, September 21st will be paid a dividend of $0.06 per share. This represents a $0.24 annualized dividend and a yield of 0.81%. The ex-dividend date of this dividend is Thursday, September 20th. Luminex’s payout ratio is currently 26.37%.

Several analysts recently issued reports on LMNX shares. Zacks Investment Research downgraded Luminex from a “hold” rating to a “sell” rating in a report on Wednesday, August 8th. Citigroup raised their price target on Luminex from $23.00 to $34.00 and gave the stock a “$33.58” rating in a report on Monday, July 23rd. BidaskClub raised Luminex from a “buy” rating to a “strong-buy” rating in a report on Thursday, May 24th. ValuEngine downgraded Luminex from a “strong-buy” rating to a “buy” rating in a report on Wednesday, August 8th. Finally, Jefferies Financial Group reaffirmed a “hold” rating and set a $27.00 target price on shares of Luminex in a research note on Tuesday, August 7th. One research analyst has rated the stock with a sell rating, three have issued a hold rating, two have issued a buy rating and one has issued a strong buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $28.60.

In other Luminex news, Director G Walter Loewenbaum II sold 3,203 shares of Luminex stock in a transaction on Wednesday, June 20th. The stock was sold at an average price of $30.91, for a total transaction of $99,004.73. Following the sale, the director now owns 531,948 shares of the company’s stock, valued at approximately $16,442,512.68. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 7.40% of the stock is owned by insiders.

About Luminex

Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include Luminex 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; ARIES system, a sample to answer real-time PCR platform; ARIES M1 system, a single-module version of the ARIES System; and VERIGENE system, an automated multiplex-capable system.

Recommended Story: Fundamental Analysis and Choosing Stocks

Want to see what other hedge funds are holding LMNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Luminex Co. (NASDAQ:LMNX).

Institutional Ownership by Quarter for Luminex (NASDAQ:LMNX)

Receive News & Ratings for Luminex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Luminex and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Clal Insurance Enterprises Holdings Ltd Has $1.07 Million Holdings in Schlumberger Limited.
Clal Insurance Enterprises Holdings Ltd Has $1.07 Million Holdings in Schlumberger Limited.
Starbucks Co.  Position Lessened by Birinyi Associates Inc.
Starbucks Co. Position Lessened by Birinyi Associates Inc.
First National Trust Co Decreases Position in Wells Fargo & Co
First National Trust Co Decreases Position in Wells Fargo & Co
Capital Investment Counsel Inc Sells 587 Shares of Walmart Inc
Capital Investment Counsel Inc Sells 587 Shares of Walmart Inc
Brokers Set Expectations for Boston Properties, Inc.’s FY2018 Earnings
Brokers Set Expectations for Boston Properties, Inc.’s FY2018 Earnings
NOVOZYMES A/S/S  Rating Increased to Hold at Zacks Investment Research
NOVOZYMES A/S/S Rating Increased to Hold at Zacks Investment Research


© 2006-2018 Ticker Report